Payment overview · 2025
General Payments
$623.43
24 reported records · 9 companies
Healthcare provider profile · identity verified
Abel A Donka, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NIANTIC, CT · NPI 1649322686
Verified facts
What the public records show
CMS Open Payments records show Abel A Donka, MD received $623.43 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $235.32 | 37.8% | 13 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $152.22 | 24.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.39 | 14.2% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.46 | 8.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.48 | 3.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.13 | 3.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.50 | 3.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.22 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.71 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.43 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $235.32 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $209.91 | 12 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $152.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.39 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $51.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1053 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 721 | 159 |
| Eliquis | Apixaban | 616 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 118 |
| Trazodone Hcl | Trazodone Hcl | 576 | 111 |
| Lisinopril | Lisinopril | 553 | 134 |
| Furosemide | Furosemide | 462 | 111 |
| Losartan Potassium | Losartan Potassium | 454 | 103 |
| Escitalopram Oxalate | Escitalopram Oxalate | 444 | 103 |
| Omeprazole | Omeprazole | 408 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 398 | 91 |
| Gabapentin | Gabapentin | 396 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 86 |
| Potassium Chloride | Potassium Chloride | 344 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 297 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 57 |
| Sertraline Hcl | Sertraline Hcl | 254 | 52 |
| Myrbetriq | Mirabegron | 241 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 44 |
| Metformin Hcl | Metformin Hcl | 214 | 52 |
| Mirtazapine | Mirtazapine | 214 | 41 |
| Donepezil Hcl | Donepezil Hcl | 210 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 199 | 55 |
| Lorazepam | Lorazepam | 185 | 60 |
| Simvastatin | Simvastatin | 183 | 44 |
| Alprazolam | Alprazolam | 182 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 176 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 41 |
| Carvedilol | Carvedilol | 141 | 33 |
| Tramadol Hcl | Tramadol Hcl | 141 | 43 |
| Prednisone | Prednisone | 138 | 52 |
| Xarelto | Rivaroxaban | 138 | 16 |
| Amoxicillin | Amoxicillin | 136 | 108 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 28 |
| Montelukast Sodium | Montelukast Sodium | 133 | 34 |
| Clonazepam | Clonazepam | 132 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 87 |
| Allopurinol | Allopurinol | 120 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 19 |
| Spironolactone | Spironolactone | 116 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 36 |
| Memantine Hcl | Memantine Hcl | 113 | 20 |
| Bupropion Xl | Bupropion Hcl | 104 | 23 |
| Warfarin Sodium | Warfarin Sodium | 103 | 11 |
| Atenolol | Atenolol | 94 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 22 |
| Levetiracetam | Levetiracetam | 91 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 21 |
| Azithromycin | Azithromycin | 85 | 71 |
| Divalproex Sodium | Divalproex Sodium | 85 | 13 |
| Ozempic | Semaglutide | 85 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 31 |
| Januvia | Sitagliptin Phosphate | 84 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 37 |
| Finasteride | Finasteride | 81 | 19 |
| Lactulose | Lactulose | 80 | 15 |
| Baclofen | Baclofen | 77 | 11 |
| Torsemide | Torsemide | 77 | 17 |
| Famotidine | Famotidine | 76 | 21 |
| Valsartan | Valsartan | 76 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 42 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 20 |
| Entresto | Sacubitril/Valsartan | 71 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 71 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | 14 |
| Celecoxib | Celecoxib | 68 | 22 |
| Rybelsus | Semaglutide | 66 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 24 |
| Enoxaparin Sodium | Enoxaparin Sodium | 64 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 61 | 14 |
| Risperidone | Risperidone | 61 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 11 |
| Nystatin | Nystatin | 56 | 28 |
| Ondansetron Odt | Ondansetron | 56 | 19 |
| Synthroid | Levothyroxine Sodium | 56 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 55 | 34 |
| Midodrine Hcl | Midodrine Hcl | 52 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Jardiance | Empagliflozin | 50 | 11 |
| Pregabalin | Pregabalin | 50 | 15 |
| Valacyclovir | Valacyclovir Hcl | 50 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Metformin Hcl Er | Metformin Hcl | 49 | 13 |
| Bumetanide | Bumetanide | 47 | 11 |
| Cephalexin | Cephalexin | 47 | 32 |
| Nifedipine Er | Nifedipine | 46 | 13 |
| Diazepam | Diazepam | 44 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 32 |
| Digoxin | Digoxin | 38 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 38 | suppressed |
| Amantadine | Amantadine Hcl | 37 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 37 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 34 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 34 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mirabegron Er | Mirabegron | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Colchicine | Colchicine | 28 | 15 |
| Cyclosporine | Cyclosporine | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 25 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 16 |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Verapamil Sr | Verapamil Hcl | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Letrozole | Letrozole | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 12 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 12 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lorazepam Intensol | Lorazepam | 21 | 14 |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Xtampza Er | Oxycodone Myristate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Dronabinol | Dronabinol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.43 · 24 records | Novo Nordisk Inc | AREXVY, ARISTADA, CAPLYTA, Evoke, FANAPT, LEQVIO, LYBALVI, Ozempic, REXULTI, Rybelsus, SHINGRIX | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error